Deep genomic analysis of solid tumours
celldx is a tissue based comprehensive molecular profiling of solid tumours with the aim to personalise therapy options. The results are generally available within 8 working days and, in addition to the genetic analysis, also provide information on the benefit of immune checkpoint inhibitors.
celldx provides advantages whenever ...
... there has to be a fast decision about a targeted therapy.
... an immunotherapy is an option for the patient.
FAQ
The turnaround time, after which the patient or his treating doctor will receive the results, is usually 8 working days from the day the laboratory receives the tissue sample. The test report contains all genomic highlights and lists the particular therapy options.
SNVs, INDELs, CNAs, Fusions, TMB, PD-L1, MSI, MMR, HRD (Homologous recombination deficiency).
Yes, celldx can provide information if a target alteration is present. Evaluation of therapies in the need of companion diagnostics across several cancer indications is available as well as clinical trial matching across all solid tumors.
celldx provides informed decisions if an immunotherapy is beneficial using genomic signatures like microsatellite instability (MSI), tumor mutational burden (TMB) and PD-L1 status via immunostaining.
Contact
Dr. Stefan Schuster
Managing Director Europe